Display options
Cite
Wee JH, Zhang YL, Rhee CS, et al. Inhibition of Allergic Response by Intranasal Selective NF-κB Decoy Oligodeoxynucleotides in a Murine Model of Allergic Rhinitis. Allergy Asthma Immunol Res. 2017;9(1):61-69doi: 10.4168/aair.2017.9.1.61.
Wee, J. H., Zhang, Y. L., Rhee, C. S., & Kim, D. Y. (2017). Inhibition of Allergic Response by Intranasal Selective NF-κB Decoy Oligodeoxynucleotides in a Murine Model of Allergic Rhinitis. Allergy, asthma & immunology research, 9(1), 61-69. https://doi.org/10.4168/aair.2017.9.1.61
Wee, Jee Hye, et al. "Inhibition of Allergic Response by Intranasal Selective NF-κB Decoy Oligodeoxynucleotides in a Murine Model of Allergic Rhinitis." Allergy, asthma & immunology research vol. 9,1 (2017): 61-69. doi: https://doi.org/10.4168/aair.2017.9.1.61
Wee JH, Zhang YL, Rhee CS, Kim DY. Inhibition of Allergic Response by Intranasal Selective NF-κB Decoy Oligodeoxynucleotides in a Murine Model of Allergic Rhinitis. Allergy Asthma Immunol Res. 2017 Jan;9(1):61-69. doi: 10.4168/aair.2017.9.1.61. PMID: 27826963; PMCID: PMC5102837.
Copy Download .nbib Format: NLM
Share it on

Allergy Asthma Immunol Res. 2017 Jan;9(1):61-69. doi: 10.4168/aair.2017.9.1.61.

Inhibition of Allergic Response by Intranasal Selective NF-κB Decoy Oligodeoxynucleotides in a Murine Model of Allergic Rhinitis.

Allergy, asthma & immunology research

Jee Hye Wee, Yu Lian Zhang, Chae Seo Rhee, Dong Young Kim

Affiliations

  1. Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, Korea.
  2. Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, Korea. [email protected].

PMID: 27826963 PMCID: PMC5102837 DOI: 10.4168/aair.2017.9.1.61

Abstract

PURPOSE: It remains unknown whether local inhibition of Nuclear factor-kappa B (NF-κB) could have therapeutic value in the treatment of allergic rhinitis (AR). This study aimed to evaluate the effect of selective NF-κB inhibition using NF-κB decoy oligodeoxynucleotides (ODNs) for the local treatment of AR in ovalbumin (OVA)-sensitized wild-type mice.

METHODS: BALB/c mice were sensitized with OVA and alum, and then challenged intranasally with OVA. NF-κB decoy ODNs were given intranasally to the treatment group, and NF-κB scrambled ODNs were given to the sham treatment group. Allergic symptom scores, eosinophil infiltration, cytokine levels in the nasal mucosa, nasal lavage fluid, and spleen cell culture, serum total and OVA-specific immunoglobulins, as well as intercellular adhesion molecure-1 (ICAM-1) in the nasal mucosa, were analyzed.

RESULTS: NF-κB decoy ODNs significantly reduced allergic symptoms and eosinophil infiltration in the nasal mucosa. They also suppressed serum levels of total IgE, OVA-specific IgE, and IgG1. IL-5 and TNF-α levels and the expression of ICAM-1 were decreased in the nasal mucosa of the treatment group compared to the positive control and sham treatment groups. In addition, IL-6 levels were significantly decreased in the nasal lavage fluid of the treatment group. Furthermore, NF-κB decoy ODNs significantly reduced expression of the systemic Th2 cytokines, IL-4 and IL-5 in spleen cell culture.

CONCLUSIONS: This study demonstrates for the first time that local NF-κB inhibition using NF-κB decoy ODNs suppressed the allergic response in a murine AR model. This shows the therapeutic potential of local NF-κB inhibition in the control of AR.

Keywords: Allergic rhinitis; NF-kappa B; NF-kappa B decoy; anti-allergic agents; immunoglobulin E; oligodeoxyribonucleotides

Conflict of interest statement

There are no financial or other issues that might lead to conflict of interest.

References

  1. J Immunol. 2004 Nov 1;173(9):5766-75 - PubMed
  2. Immunol Lett. 2008 Aug 15;119(1-2):49-56 - PubMed
  3. Nat Med. 1997 Aug;3(8):894-9 - PubMed
  4. Otolaryngol Head Neck Surg. 2012 Dec;147(6):1012-9 - PubMed
  5. Int Arch Allergy Immunol. 2004 Feb;133(2):145-53 - PubMed
  6. Annu Rev Immunol. 1998;16:225-60 - PubMed
  7. Am J Respir Crit Care Med. 2009 Apr 15;179(8):657-65 - PubMed
  8. Discov Med. 2011 Aug;12(63):97-105 - PubMed
  9. J Immunol. 2005 Feb 1;174(3):1647-56 - PubMed
  10. Annu Rev Immunol. 1996;14:649-83 - PubMed
  11. J Invest Dermatol. 2006 Jan;126(1):97-104 - PubMed
  12. Nucleic Acids Res. 2002 Jun 1;30(11):2435-43 - PubMed
  13. Allergy Asthma Proc. 2005 Sep-Oct;26(5):336-40 - PubMed
  14. Asian Pac J Cancer Prev. 2011;12(10):2721-6 - PubMed
  15. Asian Pac J Cancer Prev. 2010;11(1):193-200 - PubMed
  16. Cell Immunol. 1991 Jun;135(1):95-104 - PubMed
  17. J Clin Invest. 2001 Jan;107(1):7-11 - PubMed
  18. Cell Death Differ. 2006 May;13(5):738-47 - PubMed
  19. Cell Immunol. 1990 Jun;128(1):31-40 - PubMed
  20. Allergy. 2011 Feb;66(2):279-86 - PubMed
  21. Gene Ther. 2003 Feb;10 (4):356-64 - PubMed
  22. Eur Arch Otorhinolaryngol. 2011 Jan;268(1):73-81 - PubMed
  23. Toxicol Pathol. 2009 Feb;37(2):249-55 - PubMed
  24. Trends Biochem Sci. 2004 Feb;29(2):72-9 - PubMed
  25. Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1329-34 - PubMed
  26. Allergy Asthma Immunol Res. 2016 May;8(3):216-22 - PubMed

Publication Types